Boston, Massachusetts--(Newsfile Corp. - June 10, 2025) - Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and pharmaceutical sectors, Dr. Gardiner brings deep translational expertise that will accelerate Tevard's mission to develop effective and durable tRNA-based therapies targeting the root cause of disease. As CSO, she will lead scientific strategy and R&D operations to expand Tevard's novel platform of engineered suppressor tRNAs, which recently demonstrated the first sustained restoration of full-length dystrophin in a Duchenne Muscular Dystrophy (DMD) model.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Dr. Gardiner's experience scaling discovery and translational programs will be critical as Tevard advances their lead program toward the clinic and expands their pipeline across additional indications.
• Tevard Biosciences is working to unlock the potential of tRNA-based therapies. The company's programs are based on its novel Suppressor tRNA technology platform that uses a viral vector to insert the normal amino acid at the site of the premature stop codon.
• Tevard's lead program targeting TTN-related dilated cardiomyopathy is advancing rapidly, with new data expected in the near future.

Click image above to view full announcement.

About Tevard Biosciences 
Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The privately held biotechnology company was founded by renowned scientists along with life science executives and entrepreneurs who are also fathers of children with rare diseases. Tevard is advancing the use of its novel suppressor tRNA platform in heart disease, muscular dystrophies, and neurological disorders. For more information, please visit www.tevard.com.

Source: Tevard

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255057